Online inquiry

IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6086MR)

This product GTTS-WQ6086MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL23A gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_016584.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51561
UniProt ID Q9NPF7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6086MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7968MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GX-17
GTTS-WQ7538MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GC-182
GTTS-WQ13162MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-04383119
GTTS-WQ3662MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ8948MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ5052MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CaCP-29
GTTS-WQ6632MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ6291MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CS-1001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW